Johnson & Johnson

Latest Headlines

Latest Headlines

How can Pradaxa, Xarelto and Eliquis finally unseat warfarin? Safety data, analyst says

New oral anticoagulants--such as Johnson & Johnson's Xarelto and Boehringer Ingelheim's Pradaxa--have been in fierce competition with one another for awhile now. But they still have a ways to go to displace the old-guard therapy warfarin--and one GlobalData analyst thinks she knows why.

J&J's DePuy pushes back at medical funding for hip implants

Johnson & Johnson is striking back at a surgical funding company for allegedly profiting on patients who are suing J&J over its all-metal hip implants and seeking corrective surgeries, a month after a new report shed light on the funder's questionable dealings with individuals involved in vaginal mesh litigation.

What do multinational drug firms want from Xi-Obama summit?

China Daily  ran a series of interviews with multinational business executives about bilateral commercial expectations ahead as U.S. President Barack Obama hosts China's President Xi Jinping at the White House for an official state visit.

J&J signs up to assess Nextera's tech platform in rheumatoid arthritis

Nextera has landed a research collaboration that could put it on the map. The deal gives Johnson & Johnson a chance to take a closer look at Nextera's immunological technology platform with a view to bagging an exclusive global license for its use in rheumatoid arthritis research.

J&J faces Tylenol lobbying allegations in first case to go to trial over med

New court documents in the first trial over claims that Johnson & Johnson promoted its blockbuster painkiller, Tylenol, without disclosing potentially dangerous side effects show that J&J's McNeil Consumer Healthcare unit planned to lobby government officials to prevent the FDA from implementing safety restrictions, ProPublica reports.

A player in J&J's hep C cocktail helps hustle a quick cure

Gilead has already made a megablockbuster fortune out of its hepatitis C cure. But the race to cure patients faster (and probably cheaper) is still on. And Achillion today posted some new data from small studies that show its NS5A inhibitor odalasvir (or ACH-3102) could feature prominently in one of the new cocktail therapies now in development at Johnson & Johnson.

J&J's Janssen strikes four-year, $28.5M government partnership to advance Ebola vaccine

Johnson & Johnson's Janssen struck a four-year, $28.5 million government partnership to further the development of the Ebola jab on which Janssen is collaborating with Bavarian Nordic. Janssen awarded Bavarian Nordic $9 million in a subcontract, the latter announced Tuesday.

AbbVie edges closer to Imbruvica deal payoff with another FDA filing

AbbVie and Johnson & Johnson are one step closer to a new use for Imbruvica. The companies went to the FDA with an app for first-line use in chronic lymphocytic leukemia (CLL), in a march toward a set of new indications the companies will need to hit their ambitious goals for the med.

J&J does a quick about-face on $1B media account move

Just a year after switching U.S. media buying partners, Johnson & Johnson is taking its $1 billion media account back to J3, a J&J-dedicated unit inside Interpublic Group's UM.

Diabetes rivalries get more complicated with new FDA warning on J&J's Invokana

SGLT2 drugs recently looked as though they might get a classwide boost when partners Eli Lilly and Boehringer Ingelheim announced a cardiac benefit for their entrant, Jardiance. But just a few weeks later, the FDA has handed Johnson & Johnson a safety setback that could give its SGLT2 rivals an advantage.